

Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2009 June ; 18(6): 1864–1868. doi:10.1158/1055-9965.EPI-08-0486.

Genetic variation in the chromosome 17q23 amplicon and breast cancer risk

Linda E Kelemen¹, Xianshu Wang², Zachary S Fredericksen³, V Shane Pankratz³, Paul DP Pharoah⁴, Shahana Ahmed⁴, Alison M Dunning⁴, Douglas F Easton⁵, Robert A Vierkant³, James R Cerhan³, Ellen L Goode³, Janet E Olson³, and Fergus J Couch²

¹ Division of Population Health, Alberta Cancer Board, Calgary, AB, Canada

² Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

³ Department of Health Sciences Research, Mayo Clinic, Rochester, MN

⁴ Department of Oncology, University of Cambridge, UK

⁵ Department of Public Health and Primary Care, University of Cambridge, UK

Abstract

Background—Gene amplification leading to over-expression is a common event in breast tumors that is linked to tumor development and progression. The 17q23 region is amplified in more than 40% of breast tumors and contains several candidate oncogenes. Because common genetic variation in several oncogenes has been associated with cancer risk, we assessed the relevance of common variants in the 17q23 candidate oncogenes to breast cancer.

Methods—We investigated 60 polymorphisms in the *TUBD1*, *SEPT4*, *PRKCA*, *TBX2*, *TBX4*, *TEX14*, *TLK2*, *YPEL2* and *PPM1E* genes from this amplicon for association with breast cancer risk among 798 Caucasian breast cancer cases and 843 unaffected Caucasian controls from the Mayo Clinic.

Results—Eight polymorphisms in *PRKCA*, *TBX4*, *TLK2*, and *YPEL2* displayed significant dose-response associations with breast cancer risk ($P_{\text{trend}} < 0.05$). Of these, *PRKCA* rs7342847 and *TLK2* rs2245092 and rs733025 were also associated with hormone receptor positive breast cancer: *PRKCA* rs7342847 (OR, 0.7; 95% CI, 0.6-0.9; $P_{\text{trend}} = 0.002$) and *TLK2* rs733025 and rs2245092 (both: OR, 0.8; 95% CI, 0.7-1.0; $P_{\text{trend}} = 0.03$). Interactions between *SEPT4* rs758377 and *TEX14* rs302864 ($P_{\text{interaction}} = 0.0003$) and between *TLK2* rs733025 and *YPEL2* rs16943468 ($P_{\text{interaction}} = 0.05$) for risk of breast cancer were also observed.

Conclusion—These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors. The findings are discussed within the context of the results from two independent datasets.

Keywords

17q23; Association; Risk factors

Introduction

Molecular cytogenetic studies have revealed common regions of DNA amplification in breast tumors (1). These regions contain oncogenes such as *Erb2* and *c-Myc* that are frequently overexpressed as a result of the amplification (2) and contribute to tumor progression. Recently, common genetic variation in oncogenes such as *FGFR2* (3) and *AURKA* (4), which are amplified and overexpressed in primary breast tumors (5-7), have been associated with an increased risk of breast cancer. This suggests that genes contributing to breast tumor progression as a result of amplification and overexpression may also influence breast cancer susceptibility through inherited genetic variation.

The chromosome 17q23 region is gained or amplified in more than 40% of breast tumors (8-10). We (11) and others (12) characterized the 4Mb amplicon on chromosome 17q23 and identified several independent peaks of amplification containing genes such as T-box transcription factor (*TBX2*) (13), Peanut-like 2 (*SEPT4*) (14), and protein phosphatase 1E (*PPM1E*) (15).

In view of the possible link between genetic variation and amplification of oncogenes in breast cancer (3), we hypothesized that common genetic variation in selected amplified genes from the 17q23 amplicon (11) – *TUBD1*, *SEPT4*, *PRKCA*, *TBX2*, *TBX4*, *TEX14*, *TLK2* and *YPEL2* – that are overexpressed in breast tumors is associated with breast cancer risk. Interestingly, these proteins are thought to influence the process of cell division and might be associated with cancer through induction of aneuploidy and/or polyploidy (14,16-21) much like *AURKA* (22). In addition, because of a recent report suggesting an association between expression of mitotic protein kinases and luminal breast cancer (23), we examined associations between genetic variation in the kinase-encoding genes, *PRKCA* and *TLK2*, and estrogen and progesterone receptor positive (ER+/PR+) breast cancer.

Materials and Methods

Mayo Clinic Study

The Mayo Clinic Breast Cancer study is an on-going clinic-based case-control study initiated in February 2001 at Mayo Clinic, Rochester, MN. The study design has been presented previously (3). Consecutive cases were women aged 18 years or over, without a prior history of cancer, diagnosed with histologically-confirmed primary invasive breast cancer within six months of recruitment. Women with no history of cancer were frequency matched on age (5-year age category) and region of residence to cases. Controls were recruited from those seeking general medical examinations at the outpatient practices at Mayo Clinic. The 798 cases and 843 controls in this study were Caucasian women (99% of study participants) who completed a self-administered risk factor questionnaire and provided blood samples for genomic DNA extraction.

SNP Selection, Genotyping and Quality Control

Tag single nucleotide polymorphisms (SNPs) and all putative functional SNPs for *TUBD1*, *SEPT4*, *TBX2*, *TBX4*, *TEX14*, *TLK2*, and *YPEL2* were identified according to previously published criteria (24). Two functional SNPs were included from *PRKCA* in place of the large number of tagSNPs in this gene. SNPs were genotyped with the GoldenGate™ Assay (Illumina Inc., San Diego, California) (25-27). Only samples and SNPs with call rates above 95% were included in analyses. Concordance between 100 duplicate samples was > 99.99%. A single SNP (rs16943326) from the *PPM1E* gene in the 17q23 amplicon that displayed a significant inverse association with postmenopausal breast cancer in Stage 1 of the Cancer Genetic Markers of Susceptibility (CGEMS) genome-wide association study (GWAS rank of 11; $P =$

0.00004) (<https://caintegrator.nci.nih.gov/cgems/>)(28) was genotyped with the Taqman® assay in the Mayo Clinic Genotyping Shared Resource.

The Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH), an ongoing population-based study of invasive breast cancer cases of European ancestry ascertained through the Eastern Cancer Registration and Information Centre in England (29), was used to further evaluate the association between *TLK2* rs2245092, the SNP most significantly associated with risk in the Mayo Clinic sample, and breast cancer. Successful genotyping was achieved for 97.6% of 4,470 cases and 4,560 controls with the Taqman® assay.

Statistical Analysis

Individual SNP associations for breast cancer risk were assessed using unconditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) using ordinal (log-additive) and co-dominant genetic models. Analyses were adjusted for age and region of residence in the Mayo Clinic sample. Observed *P*-values in the Mayo Clinic sample were compared to empirical *P*-value distributions using Monte Carlo simulation methods (30) that permuted case-control status using 2,000 iterations. The “corrected” *P*-value for the SNP with the smallest observed *P*-value was then calculated by comparing its value with the corresponding empirical distribution of permuted *P*-values. We compared ORs and 95% CIs observed in the Mayo Clinic sample with age-adjusted estimates in the SEARCH sample for *TLK2* rs2245092, and with estimates adjusted for age, race and postmenopausal hormone use among postmenopausal women in the CGEMS sample for *PPM1E* rs16943326.

In secondary analyses, interactions between pairwise combinations of the SNPs with statistically significant individual associations were evaluated by including into statistical models a product term of the coefficients for the log-additive genetic models of both SNPs and assessing significance with a likelihood ratio test. We also subset cases defined by ER+ and PR+ tumor status and compared SNP associations in the kinase-encoding genes, *PRKCA* and *TLK2* (23), between cases and all controls using unconditional logistic regression.

Results

A total of 60 SNPs (Supplementary Table S1) were examined in Mayo Clinic cases and controls. Covariates that differed in distribution by case-control status (Table 1) did not impact risk estimates when evaluated in statistical models.

Eight SNPs in four genes (*PRKCA*, *TBX4*, *TLK2* and *YPEL2*) showed significant dose-responsive ($P_{\text{trend}} < 0.05$) associations with breast cancer risk in the Mayo Clinic sample (Table 2). Decreased risks were associated with each copy of the minor allele for *PRKCA* rs7342847 ($P_{\text{trend}} = 0.02$), *TBX4* rs11867179 ($P_{\text{trend}} = 0.04$), and *TLK2* rs733025, rs12451705, rs6504112 and rs2245092 ($P_{\text{trend}} \leq 0.02$), whereas increased risk was associated with each copy of the minor allele for *TBX4* rs3744448 ($P_{\text{trend}} = 0.03$) and *YPEL2* rs16943468 ($P_{\text{trend}} = 0.03$). Two other SNPs in *SEPT4* and *YPEL2* displayed associations with breast cancer risk in co-dominant genetic models (Supplementary Table S2). Overall, the number of observed significant associations ($n=10$) was greater than the number expected by random variability ($n=3$). When compared to the permuted *P*-value distribution, none of the associations with breast cancer were statistically significant at $P < 0.05$. SNPs with observed non-significant associations with breast cancer are listed in Supplementary Table S3.

Given the similarity in ORs and the correlation between the four *TLK2* SNPs (pairwise $r^2 = 0.57-0.81$) (Table 2), we used backward elimination regression to evaluate the independent effects of *TLK2* SNPs with breast cancer. Only *TLK2* rs2245092 was retained by the model at $P = 0.01$, suggesting that rs2245092 or a variant in strong linkage disequilibrium (LD)

accounted for these associations with breast cancer. We subsequently evaluated *TLK2* rs2245092 for an association with breast cancer in the SEARCH study. The association was not confirmed: each allele was associated with an OR of 1.0 (95% CI, 0.9-1.1; $P_{\text{trend}} = 0.98$).

In exploratory analyses driven by the hypothesis that co-amplified genes may co-operate to promote tumor development, significant interactions were observed between *SEPT4* rs758377 and *TEX14* rs302864 ($P_{\text{interaction}} = 0.0003$) and between *TLK2* rs733025 and *YPEL2* rs16943468 ($P_{\text{interaction}} = 0.05$) under a log-additive genetic model.

We also evaluated associations between SNPs and hormone receptor positive breast cancer in the Mayo Clinic sample. ER+/PR+ tumors were inversely related to *PRKCA* rs7342847 (OR, 0.7; 95% CI, 0.6-0.9; $P_{\text{trend}} = 0.002$) and to *TLK2* rs22450925 and rs2245092 (both: OR, 0.8; 95% CI, 0.7-1.0; $P_{\text{trend}} = 0.03$) under log-additive genetic models (Supplementary Tables S4). None of the SNPs in either gene were associated with hormone receptor negative breast cancer (data not shown). Data from 2,018 SEARCH cases with ER+ tumor status (PR+ status was unavailable) showed no association with *TLK2* rs2245092: OR, 1.0 (95% CI, 0.9-1.1; $P_{\text{trend}} = 0.98$).

Finally, the CGEMS study reported associations with postmenopausal breast cancer risk among women with one (OR, 0.96; 376 cases) or two (OR, 0.37; $P_{2df} = 0.00004$; 29 cases) copies of the minor allele of *PPM1E* rs16943326 (MAF = 0.23 among CGEMS controls). A nonsignificant trend toward increased risk of postmenopausal breast cancer was observed for this SNP among homozygote minor allele carriers (22 cases) in the Mayo Clinic sample (Supplementary Table S3). Significant associations of other SNPs in the Mayo Clinic sample by menopausal status are shown in Supplementary Table S5.

Discussion

Common genetic variation in amplified oncogenes such as *FGFR2* has been associated recently with risk of breast cancer, suggesting that certain genes can both predispose to (3) and contribute to progression of (6) breast cancer through independent mechanisms. We observed that breast cancer risk in the Mayo Clinic sample was associated with eight common polymorphisms in the selected candidate oncogenes *PRKCA*, *TBX4*, *TLK2* and *YPEL2* on chromosome 17q23, a region we previously identified as amplified frequently in breast tumors (11). Moreover, the SNP by SNP interactions observed between *SEPT4* and *TEX14*, in particular, are intriguing given that both genes participate in the separation of the dividing cell at the end of mitosis (19,20). This supports the notion that inter-dependent mechanisms involving genes from the 17q23 amplicon may contribute to breast cancer.

We also observed significant associations between *PRKCA* kinase rs7342847 and *TLK2* kinase rs733025 and rs2245092 and hormone receptor positive tumors in the Mayo Clinic study. This observation raises the possibility that these variants predispose to specific subtypes of breast cancer, as has been observed for rs2981582 in *FGFR2*, rs13281615 in 8q24 and rs3803662 in *TNRC9*, which have recently been verified as genetic risk factors for breast cancer (31). Our findings are also intriguing given the recent suggestion that certain mitotic kinases contribute to luminal breast cancer (23). A larger sample of ER-/PR- tumors, however, is needed to confirm the absence of association observed in our study with these SNPs.

We were unable to confirm the association between *TLK2* rs2245092 and breast cancer using the SEARCH sample. Possibly, one of the other *TLK2* SNPs with which *TLK2* rs2245092 was in strong LD in the Mayo Clinic sample may have shown an association with breast cancer had it been genotyped in SEARCH. We were also unable to confirm the association reported in CGEMS between *PPM1E* rs16943326 and postmenopausal breast cancer using the Mayo Clinic data. In post-hoc evaluation of the CGEMS data, SNPs in *TUBD1*, *SEPT4*, *TBX2* and

YPEL2 were represented in both CGEMS and the Mayo Clinic samples; however, only *YPEL2* rs16943468 was significantly associated with postmenopausal breast cancer in both studies and, similar to *PPM1E* rs16943326, the ORs were in opposite directions. At a MAF of 0.06 (*YPEL2* rs16943468) or 0.22 (*PPM1E* rs16943326), if the true OR among homozygotes is in the range of 1.2 to 1.5, then a much larger study than Mayo Clinic or CGEMS would be needed to have sufficient power to confirm the association at either the conventional $P < 0.05$ or genome-wide ($P \leq 10^{-7}$) level of significance (32). It also remains possible that the distribution of other exposures may explain the differences in genetic associations with CGEMS (for example, 60% of Mayo Clinic cases did not use postmenopausal hormones vs. <30% in the NHS (33)), emphasizing the need for careful interpretation of results between study populations.

The observed significant P -values for SNPs shown to be associated with breast cancer in the Mayo Clinic sample were not supported by distributions obtained using mathematical permutation methods. However, the biologic plausibility of our hypothesis and the support from published literature of examples of oncogenes within amplicons that contribute to cancer at the level of commonly inherited variation (e.g., *FGFR2* (3)) suggest the findings are at least as plausible as the explanation of random variability (34). Replication in similar populations of adequate sample size, therefore, should be the standard that determines the significance of other potentially promising associations cited in this report.

It is plausible that a proportion of women at risk of breast cancer due to chromosome 17q23 polymorphisms may also have gene amplification in this chromosomal region or that other biological or clinical features may modify the genetic associations. Although tissues and clinical data were unavailable for evaluation in the present report, we are pursuing these hypotheses for future investigation.

In conclusion, this study may suggest a role for genetic variation within candidate oncogenes from the 17q23 amplicon in predisposition to breast cancer. Further studies will be critical to clarify the importance of these findings.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Support: National Institutes of Health (P50 CA116201, R01 CA87898 and R01 CA122340).

References

1. Knuutila S, Bjorkqvist AM, Autio K, et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. *Am J Pathol* 1998;152:1107–23. [PubMed: 9588877]
2. Aulmann S, Adler N, Rom J, et al. c-myc amplifications in primary breast carcinomas and their local recurrences. *J Clin Pathol* 2006;59:424–8. [PubMed: 16497871]
3. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* 2007;447:1087–93. [PubMed: 17529967]
4. Ewart-Toland A, Dai Q, Gao YT, et al. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. *Carcinogenesis* 2005;26:1368–73. [PubMed: 15802297]
5. Penault-Llorca F, Bertucci F, Adelaide J, et al. Expression of FGF and FGF receptor genes in human breast cancer. *Int J Cancer* 1995;61:170–6. [PubMed: 7705943]

6. Heiskanen M, Kononen J, Barlund M, et al. CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. *Anal Cell Pathol* 2001;22:229–34. [PubMed: 11564899]
7. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okanao Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. *Cancer Res* 1999;59:2041–4. [PubMed: 10232583]
8. Kallioniemi A, Kallioniemi OP, Piper J, et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. *Proc Natl Acad Sci USA* 1994;91:2156–60. [PubMed: 8134364]
9. Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. *Cancer Res* 1997;57:1222–7. [PubMed: 9102202]
10. Kuukasjarvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. *Cancer Res* 1997;57:1597–604. [PubMed: 9108466]
11. Wu G, Sinclair C, Hinson S, Ingle JN, Roche PC, Couch FJ. Structural analysis of the 17q22–23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors. *Cancer Res* 2001;61:4951–5. [PubMed: 11431322]
12. Monni O, Barlund M, Mousses S, et al. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. *Proc Natl Acad Sci USA* 2001;98:5711–6. [PubMed: 11331760]
13. Jacobs JJ, Keblusek P, Robanus-Maandag E, et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. *Nat Genet* 2000;26:291–9. [PubMed: 11062467]
14. Paavola P, Horelli-Kuitunen N, Palotie A, Peltonen L. Characterization of a novel gene, PNTL2, on human chromosome 17q22–q23 and its exclusion as the Meckel syndrome gene. *Genomics* 1999;55:122–5. [PubMed: 9889007]
15. Koh CG, Tan EJ, Manser E, Lim L. The p21-activated kinase PAK is negatively regulated by POPX1 and POPX2, a pair of serine/threonine phosphatases of the PP2C family. *Curr Biol* 2002;12:317–21. [PubMed: 11864573]
16. Morse-Gaudio M, Connolly JM, Rose DP. Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. *Int J Oncol* 1998;12:1349–54. [PubMed: 9592198]
17. Ways DK, Kukoly CA, deVente J, et al. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. *J Clin Invest* 1995;95:1906–15. [PubMed: 7706498]
18. Carrera P, Moshkin YM, Gronke S, et al. Tousled-like kinase functions with the chromatin assembly pathway regulating nuclear divisions. *Genes Dev* 2003;17:2578–90. [PubMed: 14561777]
19. Greenbaum MP, Ma L, Matzuk MM. Conversion of midbodies into germ cell intercellular bridges. *Dev Biol* 2007;305:389–96. [PubMed: 17383626]
20. Glotzer M. The molecular requirements for cytokinesis. *Science* 2005;307:1735–9. [PubMed: 15774750]
21. Sinclair CS, Adem C, Naderi A, et al. TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. *Cancer Res* 2002;62:3587–91. [PubMed: 12097257]
22. Wang X, Zhou YX, Qiao W, et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. *Oncogene* 2006;25:7148–58. [PubMed: 16715125]
23. Finetti P, Cervera N, Charafe-Jauffret E, et al. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. *Cancer Res* 2008;68:767–76. [PubMed: 18245477]
24. Wang X, Goode EL, Fredericksen ZS, et al. Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2008;17:2101–8. [PubMed: 18708403]
25. Steemers FJ, Gunderson KL. Illumina, Inc. *Pharmacogenomics* 2005;6:777–82. [PubMed: 16207153]

26. Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. *Biotechniques* 2002;(Suppl):56–8. 60–1. [PubMed: 12083399]
27. Fan JB, Oliphant A, Shen R, et al. Highly parallel SNP genotyping. *Cold Spring Harb Symp Quant Biol* 2003;68:69–78. [PubMed: 15338605]
28. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in *FGFR2* associated with risk of sporadic postmenopausal breast cancer. *Nature Genet* 2007;39:870–4. [PubMed: 17529973]
29. Pharoah PD, Tyrer J, Dunning AM, et al. Association between common variation in 120 candidate genes and breast cancer risk. *PLoS Genet* 2007;3:e42. [PubMed: 17367212]
30. Westfall, PH.; Young, SS. Resampling-based multiple testing. New York: John Wiley and Sons, Inc.; 1993. p. 66-7.
31. Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. *PLoS Genet* 2008;4:e1000054. [PubMed: 18437204]
32. Chanock SJ, Manolio T, Boehnke M, et al. Replicating genotype-phenotype associations. *Nature* 2007;447:655–60. [PubMed: 17554299]
33. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. *Cancer Epidemiol Biomarkers Prev* 2008;17:2029–35. [PubMed: 18708395]
34. Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology* 1990;1:43–6. [PubMed: 2081237]

Table 1

Demographic, personal and lifestyle characteristics among breast cancer cases and controls*, Mayo Clinic, 2001-2005.

Characteristic	Level	Cases n=798		Controls n=843	
		N	%	N	%
Age, years	20-39	56	7	48	6
	40-49	192	24	166	20
	50-59	224	28	274	32
	60-69	195	24	207	25
	70+	131	16	148	18
State of residence [†]	MN	502	63	552	66
	Other	296	37	291	34
Family history [‡]	Yes	366	47	345	43
	Yes	480	64	579	72
Age at menarche, years	< 12	132	18	122	16
	12	224	31	184	24
	13	218	30	238	32
	≥ 14	154	21	209	28
	0 Months	430	58	366	49
Postmenopausal hormone use	1-60 Months	131	18	160	22
	60+ Months	184	25	216	29
	None	467	63	500	66
Smoking, packyears	≤ 4 years	46	6	67	9
	> 4 years	231	31	192	25
Tumor status	Positive	486	82		
	Negative	109	18		
	Positive	440	74		
Progesterone receptor	Negative	152	26		

*Ns may not total 798 cases and 843 controls due to missing data; Percentages may not total 100 due to rounding.

[†]Other refers to IA, IL, WI, ND and SD

#Family history in 1st or 2nd degree relative with breast or ovarian cancer.

Selected adjusted * odds ratios (OR) and 95% confidence intervals (CI) between polymorphisms in genes on the chromosome 17q23 amplicon and breast cancer risk, Mayo Clinic, 2001–2005.

Table 2

Gene/SNP rsID	Per allele	P trend	Homozygotes common allele (Referent)		Heterozygotes [†]		Homozygotes rare allele [‡]		P 2df [‡]										
			OR (95% CI)	Ca [§]	Co [§]	Ca	Co	OR (95% CI)		Ca	Co	OR (95% CI)							
PRKCA																			
rs7342847	0.8 (0.7-1.0)	0.02	335	290	344	426	119	127	0.8 (0.6-1.1)	0.005									
TBX4																			
rs11867179	0.8 (0.7-1.0)	0.04	445	451	310	319	43	73	0.6 (0.4-0.9)	0.03									
rs3744448	1.2 (1.0-1.5)	0.03	559	634	217	189	22	20	1.3 (0.7-2.4)	0.08									
TLK2																			
rs733025	0.8 (0.7-0.9)	0.006	378	345	339	395	81	103	0.7 (0.5-1.0)	0.02									
rs12451705	0.8 (0.7-1.0)	0.02	260	226	374	427	163	189	0.7 (0.6-1.0)	0.02									
rs6504112	0.8 (0.7-0.9)	0.008	314	285	365	404	119	154	0.7 (0.5-0.9)	0.03									
rs2245092	0.8 (0.7-0.9)	0.005	356	325	357	405	85	113	0.7 (0.5-0.9)	0.02									
YPEL2																			
rs16943468	1.3 (1.1-1.8)	0.03	679	745	113	95	6	3	2.1 (0.5-8.7)	0.10									

* Adjusted for age and region of residence.

[†] Referent is homozygous common allele group.

[‡] 2-degree-of-freedom P value.

[§] Ca, cases; Co, controls.